Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company`s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Website: centurytx.com


  • Bad financial results growth rate 0.0% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (100.0%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -529.3% (LTM)
  • Share price is 44.4% higher than minimum and 95.1% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (0.3x vs 0.3x)

Key Financials (Download financials)

Ticker: IPSC
Share price, USD:  (0.0%)0.5618
year average price 0.9391  


year start price 1.7100 2024-08-19

max close price 2.0200 2024-08-26

min close price 0.3891 2025-04-08

current price 0.5618 2025-08-18
Common stocks: 58 850 300

Dividend Yield:  0.0%
EV / Sales: -19.5x
Margin (EBITDA LTM / Revenue): -6 150.0%

Target EV / EBITDA (hist percentile): 0.3x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 33
Net Debt ($m): -72
EV (Enterprise Value): -39
EBITDA LTM (млн $): -123
Price to Book: 0.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-15zacks.com

Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock

2025-05-15zacks.com

Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates

2025-03-19zacks.com

Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates

2024-11-05zacks.com

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

2024-11-05globenewswire.com

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

2024-07-09zacks.com

Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade

2024-05-09Zacks Investment Research

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates

2024-04-23GlobeNewsWire

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

2024-03-19GlobeNewsWire

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

2024-03-07Zacks Investment Research

How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IPSC IPSC IPSC IPSC IPSC IPSC IPSC IPSC IPSC
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-05 2024-08-08 2024-05-09 2024-03-14 2023-11-09 2023-08-09 2023-05-11 2023-03-16 2022-11-10
acceptedDate 2024-11-05 09:05:51 2024-08-08 07:30:38 2024-05-09 07:30:49 2024-03-14 07:30:58 2023-11-09 07:00:34 2023-08-09 07:30:39 2023-05-11 07:30:46 2023-03-16 07:30:44 2022-11-10 07:30:47
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 791 000 771 000 855 000 268 000 148 000 99 000 2M 521 000 2M
costOfRevenue 3M 3M 3M 4M 2M 2M 0 0 0
grossProfit -3M -3M -2M -3M -2M -2M 2M 521 000 2M
grossProfitRatio -3.168 -3.49 -2.773 -12.254 -11.074 -23.333 1 1 1
researchAndDevelopmentExpenses 27M 24M 20M 22M 23M 23M 25M 26M 26M
generalAndAdministrativeExpenses 8M 8M 9M 9M 9M 8M 9M 8M 8M
sellingAndMarketingExpenses 0 782 000 0 -4M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 8M 9M 9M 5M 9M 8M 9M 8M 8M
otherExpenses 0 -12 000 11 000 -15 000 12 000 -186 000 -194 000 2M 0
operatingExpenses 36M 33M 29M 27M 32M 31M 34M 34M 34M
costAndExpenses 36M 36M 32M 31M 32M 31M 34M 34M 34M
interestIncome 3M 4M 3M 4M 3M 3M 3M -964 000 0
interestExpense 0 0 0 -1M 0 136 000 404 000 318 000 296 000
depreciationAndAmortization 3M 3M 3M 4M 3M 3M 2M 5M 4M
ebitda -28M -28M -28M -27M -28M -25M -30M -28M -28M
ebitdaratio -35.319 -41.602 -32.846 -100.989 -190.054 -250.01 -17.24 -54.691 -12.434
operatingIncome -35M -36M -31M -31M -36M -35M -32M -33M -32M
operatingIncomeRatio -43.981 -46.092 -36.619 -114.243 -240.716 -354.313 -18.652 -63.927 -14.271
totalOtherIncomeExpensesNet 4M 4M 3M -10M -4M -4M 2M 2M 1M
incomeBeforeTax -31M -31M -28M -40M -32M -32M -30M -32M -31M
incomeBeforeTaxRatio -39.487 -40.447 -32.82 -150.25 -217.081 -326.677 -17.474 -60.749 -13.815
incomeTaxExpense -8000 22 000 1000 -869 000 592 000 950 000 1M 32 000 25 000
netIncome -31M -31M -28M -39M -33M -33M -31M -32M -31M
netIncomeRatio -39.477 -40.476 -32.821 -147.007 -221.081 -336.273 -18.177 -60.81 -13.826
eps -0.37 -0.38 -0.45 -0.66 -0.55 -0.56 -0.53 -0.55 -0.53
epsdiluted -0.37 -0.38 -0.45 -0.66 -0.55 -0.56 -0.53 -0.55 -0.53
weightedAverageShsOut 85M 82M 62M 60M 59M 59M 59M 58M 58M
weightedAverageShsOutDil 85M 82M 62M 60M 59M 59M 59M 58M 58M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IPSC IPSC IPSC IPSC IPSC IPSC IPSC IPSC IPSC
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-05 2024-08-08 2024-05-09 2024-03-14 2023-11-09 2023-08-09 2023-05-11 2023-03-16 2022-11-10
acceptedDate 2024-11-05 09:05:51 2024-08-08 07:30:38 2024-05-09 07:30:49 2024-03-14 07:30:58 2023-11-09 07:00:34 2023-08-09 07:30:39 2023-05-11 07:30:46 2023-03-16 07:30:44 2022-11-10 07:30:47
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 53M 41M 47M 47M 55M 64M 87M 84M 111M
shortTermInvestments 146M 155M 145M 125M 114M 92M 165M 231M 245M
cashAndShortTermInvestments 198M 196M 192M 173M 170M 156M 251M 315M 356M
netReceivables 0 0 0 665 000 2M 2M 1M 780 000 364 000
inventory 0 0 0 0 -2M -2M -1M 0 0
otherCurrentAssets 8M 12M 8M 4M 4M 5M 4M 3M 5M
totalCurrentAssets 206M 203M 200M 177M 174M 161M 256M 320M 362M
propertyPlantEquipmentNet 94M 98M 88M 92M 107M 109M 114M 112M 107M
goodwill 5M 5M 0 0 0 0 0 0 0
intangibleAssets 34M 33M 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 39M 38M 0 0 0 0 0 0 0
longTermInvestments 47M 76M 60M 91M 115M 145M 83M 52M 39M
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 3M 541 000 544 000 540 999 3M 3M 3M 3M 3M
totalNonCurrentAssets 183M 213M 149M 184M 224M 256M 200M 167M 150M
otherAssets 0 0 0 1 0 0 0 0 0
totalAssets 389M 416M 349M 361M 398M 417M 456M 487M 512M
accountPayables 3M 3M 3M 3M 6M 4M 3M 5M 6M
shortTermDebt 4M 4M 2M 2M 2M 1M 10M 7M 5M
taxPayables 0 0 0 0 851 000 0 0 0 0
deferredRevenue 4M 4M 5M 4M 4M 7M 7M 7M 8M
otherCurrentLiabilities 10M 8M 6M 9M 9M 7M 7M 10M 9M
totalCurrentLiabilities 20M 19M 16M 18M 20M 19M 28M 30M 27M
longTermDebt 51M 53M 44M 47M 46M 41M 41M 42M 43M
deferredRevenueNonCurrent 110M 110M 110M 111M 112M 109M 110M 111M 111M
deferredTaxLiabilitiesNonCurrent 4M 3M 0 0 0 0 0 0 0
otherNonCurrentLiabilities 9M 9M 20 000 56 000 201 000 361 000 433 000 718 000 137M
totalNonCurrentLiabilities 173M 175M 155M 158M 158M 150M 151M 154M 155M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 55M 56M 44M 47M 46M 42M 41M 39M 37M
totalLiabilities 193M 194M 171M 176M 178M 170M 179M 184M 182M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 9000 8000 6000 6000 6000 6000 6000 6000 6000
retainedEarnings -746M -715M -684M -656M -616M -584M -550M -519M -487M
accumulatedOtherComprehensiveIncomeLoss 758 000 -309 000 -241 000 108 000 -1M -1M -1M -2M -4M
othertotalStockholdersEquity 941M 937M 862M 840M 837M 832M 829M 824M 821M
totalStockholdersEquity 196M 222M 178M 185M 219M 248M 277M 303M 330M
totalEquity 196M 222M 178M 185M 219M 248M 277M 303M 330M
totalLiabilitiesAndStockholdersEquity 389M 416M 349M 361M 398M 417M 456M 487M 512M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 389M 416M 349M 361M 398M 417M 456M 487M 512M
totalInvestments 192M 231M 205M 216M 229M 237M 248M 283M 284M
totalDebt 55M 56M 46M 48M 46M 42M 51M 49M 47M
netDebt 2M 15M -346 000 847 000 -10M -22M -35M -35M -64M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IPSC IPSC IPSC IPSC IPSC IPSC IPSC IPSC IPSC
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-05 2024-08-08 2024-05-09 2024-03-14 2023-11-09 2023-08-09 2023-05-11 2023-03-16 2022-11-10
acceptedDate 2024-11-05 09:05:51 2024-08-08 07:30:38 2024-05-09 07:30:49 2024-03-14 07:30:58 2023-11-09 07:00:34 2023-08-09 07:30:39 2023-05-11 07:30:46 2023-03-16 07:30:44 2022-11-10 07:30:47
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -31M -31M -28M -39M -33M -33M -31M -32M -31M
depreciationAndAmortization 3M 3M 3M 4M 3M 3M 3M 3M 3M
deferredIncomeTax 0 0 0 -14M 0 4M 0 0 0
stockBasedCompensation 3M 4M 3M 4M 4M 3M 4M 3M 3M
changeInWorkingCapital -3M 713 000 -9M -3M 12M 4M -4M 3M 412 000
accountsReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables -757 000 -2M 689 000 -3M 4M -514 000 -3M -2M 706 000
otherWorkingCapital -2M 3M -10M -24 000 8M 5M -1M 4M -294 000
otherNonCashItems -949 000 9M 9M 23M -437 000 -787 000 -682 000 614 000 538 000
netCashProvidedByOperatingActivities -28M -27M -30M -26M -14M -19M -29M -23M -24M
investmentsInPropertyPlantAndEquipment 804 000 -265 000 -539 000 -980 000 -3M -5M -5M -6M -10M
acquisitionsNet 0 -10M 0 92M -7M -11M -73M -238M 0
purchasesOfInvestments -13M -54M -35M -10M -57M -99M -43M -50M -66M
salesMaturitiesOfInvestments 52M 30M 47M 29M 65M 110M 79M 52M 99M
otherInvestingActivites 21 000 -24M 12M 20M 7M 11M 73M 238M 0
netCashUsedForInvestingActivites 39M -34M 12M 19M 4M 7M 31M -4M 23M
debtRepayment 0 0 0 -10M 0 -10M 0 0 0
commonStockIssued 273 000 57M 366 000 -356 000 300 000 124 000 448 000 95 000 138 000
commonStockRepurchased 0 0 0 -356 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 18M 10M 300 000 0 0 0 0
netCashUsedProvidedByFinancingActivities 273 000 57M 18M -356 000 300 000 -10M 448 000 95 000 138 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash 14M -5M -512 000 -8M -9M -22M 3M -27M -1M
cashAtEndOfPeriod 55M 41M 47M 47M 57M 66M 89M 86M 113M
cashAtBeginningOfPeriod 41M 47M 47M 55M 66M 89M 86M 113M 115M
operatingCashFlow -28M -27M -30M -26M -14M -19M -29M -23M -24M
capitalExpenditure 804 000 -265 000 -539 000 -980 000 -3M -5M -5M -6M -10M
freeCashFlow -28M -28M -31M -27M -17M -24M -34M -29M -34M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-05 14:05 ET
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
2024-11-05 14:00 ET
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
2024-11-04 12:00 ET
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
2024-09-26 11:00 ET
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
2024-08-08 11:30 ET
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
2024-06-03 11:00 ET
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
2024-05-10 11:00 ET
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
2024-05-09 11:30 ET
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
2024-04-23 11:00 ET
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
2024-04-11 11:00 ET
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
2024-04-08 20:05 ET
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
2024-03-19 11:00 ET
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
2024-03-14 11:30 ET
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
2024-03-05 23:03 ET
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
2024-02-01 12:00 ET
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2023-12-09 17:00 ET
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
2023-12-06 12:30 ET
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
2023-12-06 12:30 ET
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
2023-11-21 12:00 ET
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
2023-11-09 12:01 ET
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
2023-11-09 12:00 ET
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
2023-11-09 12:00 ET
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
2023-11-02 13:00 ET
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
2023-09-26 11:00 ET
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
2023-08-09 11:30 ET
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
2023-05-11 11:30 ET
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
2023-04-17 11:00 ET
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
2023-04-12 12:30 ET
Century Therapeutics Announces Leadership Changes
2023-03-16 11:30 ET
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
2023-03-15 20:01 ET
Century Therapeutics to Present at the AACR Annual Meeting 2023
2023-02-21 12:00 ET
Century Therapeutics to Present at Upcoming Investor Conferences
2023-02-08 12:30 ET
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
2023-02-01 12:00 ET
Century Therapeutics to Present at Upcoming Investor Conferences
2023-01-05 21:01 ET
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
2023-01-04 12:00 ET
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-11-22 12:00 ET
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
2022-11-11 12:00 ET
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
2022-11-10 12:30 ET
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
2022-11-02 11:05 ET
Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022
2022-10-05 20:05 ET
Century Therapeutics to Present at the SITC 37th Annual Meeting
2022-10-03 11:00 ET
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
2022-09-26 11:00 ET
Century Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
2022-09-06 11:00 ET
Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
2022-08-25 11:30 ET
Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection
2022-08-11 11:30 ET
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
2022-06-24 20:30 ET
Century Therapeutics Announces Its Addition to the Russell Microcap® Index
2022-06-21 20:30 ET
Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium
2022-06-06 11:30 ET
Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022
2022-05-16 11:30 ET
Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
2022-05-03 20:30 ET
Century Therapeutics to Present at Upcoming Investor Conferences
2022-05-02 20:30 ET
Century Therapeutics to Present at the ASGCT 25th Annual Meeting
2022-04-18 20:30 ET
Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
2022-04-06 20:30 ET
Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
2022-03-23 20:30 ET
Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference
2022-03-17 11:30 ET
Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates
2022-02-09 21:05 ET
Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2022-01-10 11:59 ET
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
2022-01-10 11:59 ET
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
2022-01-04 21:30 ET
Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-17 12:00 ET
Century Therapeutics Added to the NASDAQ Biotechnology Index
2021-12-16 11:30 ET
Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates
2021-11-22 13:00 ET
Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
2021-11-10 12:30 ET
Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
2021-11-04 13:00 ET
Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update
2021-10-07 11:30 ET
Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering
2021-09-17 20:01 ET
Century Therapeutics Announces Its Addition to the Russell 2000® Index
2021-08-12 12:00 ET
Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
2021-06-22 20:01 ET
Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-06-17 22:15 ET
Century Therapeutics Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2025-08-14 20:21 ET
Century Therapeutics, Inc. reported for 2025 q2
SEC form 8
2025-08-14 20:17 ET
Century Therapeutics, Inc. published news for 2025 q2
SEC form 8
2025-08-14 20:17 ET
Century Therapeutics, Inc. reported for 2025 q2
SEC form 8
2025-08-14 20:17 ET
Century Therapeutics, Inc. published news for 2025 q2
SEC form 10
2025-05-15 20:15 ET
Century Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-15 20:15 ET
Century Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-05-15 20:15 ET
Century Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-15 20:15 ET
Century Therapeutics, Inc. published news for 2025 q1
SEC form 10
2025-05-15 00:00 ET
Century Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-03-19 20:08 ET
Century Therapeutics, Inc. published news for 2024 q4
SEC form 8
2025-03-19 20:08 ET
Century Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-03-19 20:08 ET
Century Therapeutics, Inc. published news for 2024 q4
SEC form 10
2025-03-19 20:07 ET
Century Therapeutics, Inc. reported for 2024 q4
SEC form 10
2025-03-19 00:00 ET
Century Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Century Therapeutics, Inc. published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Century Therapeutics, Inc. published news for 2024 q4
SEC form 8
2024-11-05 09:10 ET
Century Therapeutics, Inc. published news for 2024 q3
SEC form 8
2024-11-05 09:10 ET
Century Therapeutics, Inc. reported for 2024 q3
SEC form 8
2024-11-05 09:10 ET
Century Therapeutics, Inc. published news for 2024 q3
SEC form 10
2024-11-05 09:05 ET
Century Therapeutics, Inc. reported for 2024 q3
SEC form 8
2024-08-08 07:37 ET
Century Therapeutics, Inc. published news for 2024 q2
SEC form 8
2024-08-08 07:37 ET
Century Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-08 07:37 ET
Century Therapeutics, Inc. published news for 2024 q2
SEC form 10
2024-08-08 07:30 ET
Century Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Century Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Century Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Century Therapeutics, Inc. published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Century Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-03-14 07:45 ET
Century Therapeutics, Inc. published news for 2023 q4
SEC form 8
2024-03-14 07:45 ET
Century Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-14 07:45 ET
Century Therapeutics, Inc. published news for 2023 q4
SEC form 10
2024-03-14 07:30 ET
Century Therapeutics, Inc. reported for 2023 q4
SEC form 10
2024-03-14 00:00 ET
Century Therapeutics, Inc. reported for 2023 q4
SEC form 8
2023-11-09 07:56 ET
Century Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-09 07:00 ET
Century Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Century Therapeutics, Inc. reported for 2023 q3
SEC form 6
2023-08-09 07:40 ET
Century Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-09 07:30 ET
Century Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Century Therapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Century Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-06-29 16:05 ET
Century Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-05-11 07:45 ET
Century Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-11 07:30 ET
Century Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Century Therapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Century Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-05 16:46 ET
Century Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-05-05 16:40 ET
Century Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-28 16:05 ET
Century Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-17 16:14 ET
Century Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-03-20 07:30 ET
Century Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-16 07:45 ET
Century Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-16 07:30 ET
Century Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-16 00:00 ET
Century Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-16 00:00 ET
Century Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-13 07:30 ET
Century Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-01-09 07:00 ET
Century Therapeutics, Inc. published news for 2022 q4
SEC form 6
2022-11-30 07:30 ET
Century Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-11-10 17:17 ET
Century Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-11-10 07:31 ET
Century Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-10 07:30 ET
Century Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Century Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Century Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-10-03 16:06 ET
Century Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-10-03 16:03 ET
Century Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-10-03 07:09 ET
Century Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-09-08 07:30 ET
Century Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-08-25 07:46 ET
Century Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-08-11 08:00 ET
Century Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-11 07:31 ET
Century Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Century Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Century Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-07-01 16:31 ET
Century Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-06-13 16:19 ET
Century Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-06-10 16:17 ET
Century Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-16 07:31 ET
Century Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-16 07:30 ET
Century Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Century Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Century Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-10 09:01 ET
Century Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-21 16:05 ET
Century Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-13 09:00 ET
Century Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-17 17:01 ET
Century Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-17 08:00 ET
Century Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-17 00:00 ET
Century Therapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-17 00:00 ET
Century Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-13 08:30 ET
Century Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-11 13:20 ET
Century Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-10 07:30 ET
Century Therapeutics, Inc. published news for 2021 q4
SEC form 6
2021-12-16 07:30 ET
Century Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-18 08:00 ET
Century Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 08:30 ET
Century Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-10 07:40 ET
Century Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Century Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Century Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-13 08:09 ET
Century Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-08-12 10:05 ET
Century Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-12 08:17 ET
Century Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Century Therapeutics, Inc. published news for 2021 q2
SEC form 8
2021-08-12 00:00 ET
Century Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-06-25 16:30 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-23 17:00 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:28 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:09 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:07 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:05 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:04 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:03 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:03 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:02 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:02 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:01 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:01 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 17:00 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 16:59 ET
Century Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 16:58 ET
Century Therapeutics, Inc. published news for 2021 q1